Addressing Racial Disparities in Health Care
Could Durvalumab (Imfinzi) Improve Survival in Early-Stage NSCLC?
The PACIFIC trial revealed a clear survival benefit to giving durvalumab to patients with stage III unresectable non-small cell lung cancer (NSCLC) following chemoradiation. With the PACIFIC-4 study, researchers want to learn whether patients might benefit from this checkpoint inhibitor in the earlier stages of the disease.Learn More
Latest Outcomes from the PACIFIC Trial Suggest Overall Survival Improvement for Lung Cancer
“The most updated outcome of the PACIFIC trial, released a couple of months ago, shows the four-year overall survival data,” says Dr. Balazs Halmos, medical oncologist and director of the Thoracic Oncology Program at Montefiore Medical Center. That, he says, is continuing to look very impressive with each year’s update.Learn More
The PACIFIC Trial Marks Major Breakthrough in Stage III Lung Cancer Treatment
Nearly one-third of patients with non-small cell lung cancer (NSCLC) present at stage III, most with unresectable tumors. Treatments up to now have had limited success with these patients, who have faced a median survival time of approximately two years. Thanks to durvalumab (brand name: Imfinzi), the outlook is finally looking up.Learn More
Which BTK Inhibitor is Best Upfront for CLL?
Ibrutinib was once the only bruton tyrosine kinase (BTK) inhibitor. Now that acalabrutinib (brand name: Calquence) is available, you have a decision to make when choosing an upfront therapy for your chronic lymphocytic leukemia (CLL) patients. Which of these two drugs is best?Learn More
What to Consider Before Prescribing a BTK Inhibitor Such as Calquence for CLL Patients
Bruton kinase (BTK) inhibitors have only emerged in recent years, but already they have become an established therapy for chronic lymphocytic leukemia (CLL) and other hematologic malignancies. Second-generation BTK inhibitors such as acalabrutinib tend to have a better safety profile than the first-generation drugs, but side effects are still a concern.Learn More
Calquence (Acalabrutinib) Has an Advantage Over Other BTK Inhibitors in CLL Treatment
Bruton tyrosine kinase (BTK) inhibitors have proven themselves highly effective for both treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL). The first-generation BTK inhibitor ibrutinib was followed by second-generation drugs such as acalabrutinib (brand name: Calquence), zanubrutinib and tirabrutinib, which have all shown good long-term efficacy and safety.Learn More
PARP Inhibitors and Recurrent Platinum-Sensitive Ovarian Cancer
Treating Recurrence after PARP Therapy Maintenance therapy with PARP inhibitors is still relatively new There are no clear guidelines yet for how to treat women with platinum-sensitive tumors when they recur after PARP maintenance therapy New trials, such as MEDIOLA, suggest a triplet option Four years ago the FDA approved the first PARP inhibitor (niraparib) […]Learn More
Breaking Down the PAOLA Trial — Who Benefits from Olaparib (Lynparza)?
In the PAOLA trial, ovarian cancer patients received either bevacizumab alone or bevacizumab plus olaparib (brand name: Lynparza) after their frontline therapy. “And what they found in this trial was very interesting,” says Dr. John Nakayama, gynecologic oncologist with Allegheny Health Network in Pittsburgh.Learn More